DK1144671T3 - Berigede centralnervesystem-cellepopulationer - Google Patents

Berigede centralnervesystem-cellepopulationer

Info

Publication number
DK1144671T3
DK1144671T3 DK00911779T DK00911779T DK1144671T3 DK 1144671 T3 DK1144671 T3 DK 1144671T3 DK 00911779 T DK00911779 T DK 00911779T DK 00911779 T DK00911779 T DK 00911779T DK 1144671 T3 DK1144671 T3 DK 1144671T3
Authority
DK
Denmark
Prior art keywords
cell populations
nervous system
central nervous
system cell
enriched
Prior art date
Application number
DK00911779T
Other languages
English (en)
Inventor
Irving Weissman
David W Buck
Nobuko Uchida
Original Assignee
Stemcells California Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/422,844 external-priority patent/US6468794B1/en
Application filed by Stemcells California Inc filed Critical Stemcells California Inc
Application granted granted Critical
Publication of DK1144671T3 publication Critical patent/DK1144671T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
DK00911779T 1999-02-12 2000-02-11 Berigede centralnervesystem-cellepopulationer DK1144671T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11972599P 1999-02-12 1999-02-12
US09/422,844 US6468794B1 (en) 1999-02-12 1999-10-21 Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US16840799P 1999-12-01 1999-12-01
PCT/US2000/003592 WO2000047762A2 (en) 1999-02-12 2000-02-11 Enriched central nervous system cell populations

Publications (1)

Publication Number Publication Date
DK1144671T3 true DK1144671T3 (da) 2008-03-17

Family

ID=46844555

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00911779T DK1144671T3 (da) 1999-02-12 2000-02-11 Berigede centralnervesystem-cellepopulationer
DK07021550.4T DK1900811T3 (da) 1999-02-12 2000-02-11 Berigede cellepopulationer i centralnervesystemet

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07021550.4T DK1900811T3 (da) 1999-02-12 2000-02-11 Berigede cellepopulationer i centralnervesystemet

Country Status (10)

Country Link
US (1) US20070238171A1 (da)
EP (2) EP1900811B1 (da)
JP (2) JP5007003B2 (da)
AT (2) ATE473273T1 (da)
AU (2) AU780256B2 (da)
CA (1) CA2361249C (da)
DE (2) DE60044655D1 (da)
DK (2) DK1144671T3 (da)
ES (2) ES2295012T3 (da)
WO (1) WO2000047762A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
DK1144671T3 (da) * 1999-02-12 2008-03-17 Stemcells California Inc Berigede centralnervesystem-cellepopulationer
US20050042749A1 (en) 2001-05-16 2005-02-24 Carpenter Melissa K. Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease
US7250294B2 (en) 2000-05-17 2007-07-31 Geron Corporation Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
CA2409698C (en) 2000-05-17 2010-10-26 Geron Corporation Neural progenitor cell populations
AUPR540301A0 (en) 2001-06-01 2001-06-28 Walter And Eliza Hall Institute Of Medical Research, The A method of purification of cells
US20050084963A1 (en) * 2001-06-01 2005-04-21 Tailoi Chan-Ling Purification of lineage-specific cells and uses therefor
CN101974480A (zh) 2001-06-22 2011-02-16 干细胞股份有限公司 肝移植细胞、测定及其应用
EP1540348A4 (en) * 2002-08-27 2006-10-11 Stemcells California Inc ENRICHED CELLS OF STEM CELLS AND PROGENITORS OF THE CENTRAL NERVOUS SYSTEM, AND METHODS OF IDENTIFYING, ISOLATING AND ENRICHING SUCH POPULATIONS
JP4481706B2 (ja) * 2004-03-31 2010-06-16 独立行政法人科学技術振興機構 脳梗塞疾患モデルマウス
WO2008064408A1 (en) * 2006-11-27 2008-06-05 The University Of Queensland Generation of enriched populations of neural progenitor cells and their progeny
DK2114167T3 (da) * 2007-01-16 2018-09-17 Univ Rochester Ikke-humane dyr med humane gliakimæriske hjerner
JP4997613B2 (ja) * 2009-12-15 2012-08-08 独立行政法人産業技術総合研究所 ヒト神経幹細胞に選択的なモノクローナル抗体及びこれを用いたスクリーニング方法
JP5035928B2 (ja) * 2009-12-15 2012-09-26 独立行政法人産業技術総合研究所 ヒト神経幹細胞のスクリーニング方法
JP6090735B2 (ja) * 2012-03-02 2017-03-08 国立大学法人山口大学 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法
EP2956147B1 (en) 2013-02-12 2022-08-24 Reneuron Limited Method of producing microparticles
TWI482782B (zh) * 2013-05-31 2015-05-01 Univ Nat Chiao Tung 架接抗體之雙乳化核殼奈米結構

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
AU678988B2 (en) * 1992-07-27 1997-06-19 California Institute Of Technology Mammalian multipotent neural stem cells
IT1264903B1 (it) 1993-06-30 1996-10-17 Sniaricerche S C P A Cristalli liquidi metallo-organici in una matrice polimerica
US5843633A (en) 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
AU755657B2 (en) * 1997-07-04 2002-12-19 University Of Utah Research Foundation Lineage-restricted neuronal precursors
US5968829A (en) * 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
JP2002500879A (ja) * 1998-01-23 2002-01-15 イムクローン システムズ インコーポレーテッド 幹細胞の精製ポピュレーション
US6451306B1 (en) * 1998-04-15 2002-09-17 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
AU774581B2 (en) * 1998-08-31 2004-07-01 New York University Stem cells bearing an FGF receptor on the cell surface
US7105150B2 (en) * 1999-02-12 2006-09-12 Stemcells California, Inc. In vivo screening methods using enriched neural stem cells
DK1144671T3 (da) * 1999-02-12 2008-03-17 Stemcells California Inc Berigede centralnervesystem-cellepopulationer
US7037719B1 (en) * 1999-02-12 2006-05-02 Stemcells California, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US6468794B1 (en) * 1999-02-12 2002-10-22 Stemcells, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations

Also Published As

Publication number Publication date
AU2005202534A1 (en) 2005-07-07
WO2000047762A9 (en) 2002-04-11
EP1144671B1 (en) 2007-11-07
WO2000047762A2 (en) 2000-08-17
DE60037007D1 (de) 2007-12-20
AU3361800A (en) 2000-08-29
AU2005202534B2 (en) 2008-05-08
DE60044655D1 (de) 2010-08-19
WO2000047762A3 (en) 2000-12-21
ES2295012T3 (es) 2008-04-16
ATE473273T1 (de) 2010-07-15
US20070238171A1 (en) 2007-10-11
EP1144671A2 (en) 2001-10-17
JP5007003B2 (ja) 2012-08-22
ES2351170T3 (es) 2011-02-01
CA2361249A1 (en) 2000-08-17
EP1900811B1 (en) 2010-07-07
JP2010252808A (ja) 2010-11-11
JP2002536023A (ja) 2002-10-29
EP1900811A1 (en) 2008-03-19
DK1900811T3 (da) 2010-10-25
DE60037007T2 (de) 2008-08-21
CA2361249C (en) 2011-05-10
AU780256B2 (en) 2005-03-10
ATE377652T1 (de) 2007-11-15

Similar Documents

Publication Publication Date Title
DK1144671T3 (da) Berigede centralnervesystem-cellepopulationer
WO2005021728A3 (en) Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for these populations
WO2004020597A3 (en) Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
ATE514772T1 (de) Multipotente erwachsene stammzellen und verfahren zu deren isolierung
DE69939945D1 (de) Verfahren zur isolierung von stammzellen
SG152273A1 (en) Pdx1 expressing endoderm
GB0127704D0 (en) Nucleic acid enrichment
DE60231035D1 (de) Stammzellen und verfahren zu deren trennung
SG149061A1 (en) Definitive endoderm
HK1132015A1 (en) Induction of the mitochondrial permeability transition
DE60026729D1 (de) Verfahren zur modifikation von ausgewählten zellen in einer magnetischen zelltrennungsäule
NO971245L (no) In vitro-modeller for sentralnervesystemfunksjon og -dysfunksjon
PT877941E (pt) Metodo para enriquecimento em volume de uma populacao ou subpopulacao de celulas
WO2002037944A3 (en) Multiplexed cell analysis system
DE60032508D1 (de) VERFAHREN ZUR VERMEHRUNG VON NATüRLICHEN KILLERZELLEN
EP1687413A4 (en) METHOD FOR DIFFERENTIATING A MESENCHYME STEM CELL TO A NERVENZELLE AND THE NERVENZELLE CONTAINING PHARMACEUTICAL COMPOSITION AGAINST A NEURODEGENERATIVE DISEASE
ATE227996T1 (de) Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod
EP2377922A3 (en) PDX1 expressing endoderm
DK0750637T3 (da) CAI resistens, som koder for et protein, samt anvendelse deraf
IL143994A0 (en) Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
TR199801916T2 (xx) Kanser olu�umuyla ilgili genlerin belirlenmesinde kullan�lan h�cre ayr��t�rmas�.
WO2003004616A3 (en) Dendritic cell isolation methods
WO2003087405A3 (de) Verfahren zur charakterisierung von primärtumoren
EP1136823A3 (de) Verfahren zur Identifizierung und Anreicherung von zellspezifischen Zielstrukturen
DE69535039D1 (de) Cytoplasmische tyrosin kinase